Outcomes for Soft-Tissue Sarcoma in 8249 Cases from a Large State Cancer Registry

Gutierrez, Juan C.; Pérez, Eduardo A.; Franceschi, Dido; Moffat, Frederick L.; Livingstone, Alan S.; Koniaris, Leonidas G.

doi:10.1016/j.jss.2007.02.026

Cited by 171 publications

(130 citation statements)

References 24 publications

Supporting

Mentioning

103

Contrasting

Unclassified

Order By: Relevance

“…For example, liposarcoma is recognized by a number of different subtypes, namely, lipoma-like liposarcoma, myxoid liposarcoma, round cell liposarcoma and pleomorphic liposarcoma. Although these are united as a genus by the demonstration of lipoblasts, the propensity to metastasize differs widely, with lipoma-like liposarcoma having a minimal incidence of metastasis, while pleomorphic liposarcoma or the round cell variant of liposarcoma have a high risk of metastasis [25][26][27][28]. Similarly, the risk of metastasis differs between myxoid malignant fibrous histiocytoma (MFH) and pleomorphic MFH [28].…”

Section: Histotypementioning

confidence: 99%

“…Although these are united as a genus by the demonstration of lipoblasts, the propensity to metastasize differs widely, with lipoma-like liposarcoma having a minimal incidence of metastasis, while pleomorphic liposarcoma or the round cell variant of liposarcoma have a high risk of metastasis [25][26][27][28]. Similarly, the risk of metastasis differs between myxoid malignant fibrous histiocytoma (MFH) and pleomorphic MFH [28]. Tumors such as synovial sarcoma, rhabdomyosarcoma and Ewing's sarcoma are considered high-risk tumors, while dermatofibrosarcoma protuberans, a dermal sarcoma with aggressive local features, is regarded as having low risk for metastasis [29,30].…”

Section: Histotypementioning

confidence: 99%

See 1 more Smart Citation

Prognostic factors in soft-tissue sarcomas: what have we learnt?

Choong¹,

Rüdiger

2008

Expert Review of Anticancer Therapy

View full text Add to dashboard Cite

Section: Histotypementioning

confidence: 99%

Section: Histotypementioning

confidence: 99%

Prognostic factors in soft-tissue sarcomas: what have we learnt?

Choong¹,

Rüdiger

2008

Expert Review of Anticancer Therapy

View full text Add to dashboard Cite

“…discussion MFH originates from undifferentiated mesenchymal cells and comprises approximately 0.5% of all malignant tumors. 4 They can occur at any age but are more frequent in relatively older individuals, especially in the fifth and seventh decades of life. They are most commonly seen in the extremities but can occur at any localization in the body.…”

Section: Case Reportmentioning

confidence: 99%

“…In addition, sunlight, chemical agents such as phenacetin, previous surgery, trauma and fracture, bone infarct, and tumors such as Hodgkin lymphoma and multiple melanoma are predisposing factors. 4,5 Most of the patients are asymptomatic, since the lesion is located retroperitoneally and deeply, or they have nonspecific symptoms such as flank pain, fever and weight loss. C-reactive protein level and erythrocyte sedimentation rate may be found to be increased in laboratory tests.…”

Section: Case Reportmentioning

confidence: 99%

Malignant fibrous histiocytoma in a patient presenting with urinary system symptoms

Reşorlu

Karatağ

Uysal

et al. 2017

Rev. Assoc. Med. Bras.

View full text Add to dashboard Cite

Malignant fibrous histiocytoma is a rare tumor. It is most commonly seen in individuals between the fifth and seventh decades of life, in extremities, and less frequently in the retroperitoneum. Although its etiology is not clearly known, radiotherapy, chemical agents, previous history of surgery, trauma and fracture, and Hodgkin lymphoma have been blamed. Leiomyosarcoma, liposarcoma and rhabdomyosarcoma should be taken into account in differential diagnosis. It is seen on computed tomography as a mass lesion with irregular borders and density similar to that of the surrounding muscle tissue. Necrotic and hemorrhagic components in the mass are characterized as heterogeneous low density areas. Fluid-fluid levels can be detected by computed tomography and magnetic resonance imaging.

show abstract

“…Tumor size, histogenetic type, grade, surgical margin status and presence of metastases are the main prognostic factors. Most patients with extremity STS present with clinically localized disease (2,3). Lymph node metastasis is evident in <3% and distant metastasis is present in 10% at the time of primary staging (4).…”

Section: Introductionmentioning

confidence: 99%

Hyperthermic isolated limb perfusion for recurrent melanomas and soft tissue sarcomas: Feasibility and reproducibility in a multi-institutional Hellenic collaborative study

Lasithiotakis

Economou²,

Gogas³

et al. 2010

Oncol Rep

View full text Add to dashboard Cite

Abstract. Hyperthermic isolated limb perfusion with TNF-· and melphalan (TM-HILP) is a complicated surgical procedure. Herein, we present the experience of the Hellenic collaborating centers with TM-HILP for inoperable in-transit melanoma and soft tissue sarcoma (STS) of the extremities to examine safety and feasibility of collaborating as a multiinstitutional group for future research studies. From 2001 to 2009, twenty patients (median age 63.5 years) underwent TM-HILP for locally advanced in-transit melanoma (n=14) or unresectable STS (n=6). All patients underwent a 90-min isolated limb perfusion with melphalan (10 mg/l limb volume) and TNF-· (1-2 mg) under mild hyperthermia (39-40˚C). No major intra-operative complications occurred and all patients completed the procedure successfully. One patient developed postoperative ischemic necrosis of the limb necessitating amputation. All melanoma patients showed a response to TM-HILP with 7 (62%) of them experiencing complete response. All STS patients attained complete response after excision of residual tumor. The median disease specific and limb-relapse-free survival was 15 and 12 months, respectively. TM-HILP can be safely applied even in low volume tertiary hospitals provided that technology to minimize intraoperative systemic leakage is available. Future prospective studies can be performed reproducibly by this multi-institutional collaborative group.

show abstract

Outcomes for Soft-Tissue Sarcoma in 8249 Cases from a Large State Cancer Registry

Cited by 171 publications

References 24 publications

Prognostic factors in soft-tissue sarcomas: what have we learnt?

Prognostic factors in soft-tissue sarcomas: what have we learnt?

Malignant fibrous histiocytoma in a patient presenting with urinary system symptoms

Hyperthermic isolated limb perfusion for recurrent melanomas and soft tissue sarcomas: Feasibility and reproducibility in a multi-institutional Hellenic collaborative study

Contact Info

Product

Resources

About